Kimberly D. Hill

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson et al. · Journal of Clinical Oncology · 1998 · 408 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +15

Design, Synthesis, and Evaluation of In Vivo Potency and Selectivity of Epoxysuccinyl-Based Inhibitors of Papain-Family Cysteine Proteases

Amir Masoud Sadaghiani, Steven H. L. Verhelst, Vasilena Gocheva et al. · Chemistry & Biology · 2007 · 75 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14

Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases

Jiamo Lu, Prabhakar Risbood, Charles T. Kane et al. · Biochemical Pharmacology · 2017 · 32 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose in Patients with Advanced Malignancies

Shivaani Kummar, Larry Anderson, Kimberly D. Hill et al. · Clinical Cancer Research · 2013 · 21 citations · Full text

Medicine, Oncology, Pharmacology +12

Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection

Sherman F. Stinson, Kimberly D. Hill, Timothy J. Siford et al. · Cancer Chemotherapy and Pharmacology · 1998 · 20 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +16